ArticleUrolithiasis2024
Identification of potential pathogenic genes for urolithiasis through multi-omics Mendelian randomization analysis.
Article in Urolithiasis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- DNA Methylation-Mediated Downregulation ofInternational journal of chronic obstructive pulmonary disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urolithiasis, a common urological disorder affecting about 10% of the global population, is known for its high recurrence rate, yet its genetic mechanisms remain poorly understood. This study aimed to fill this gap by identifying potential pathogenic genes associated with urolithiasis using a multi-omics Mendelian randomization approach. We conducted a comprehensive analysis that integrated genome-wide association studies (GWAS), expression quantitative trait loci (eQTL), methylation quantitative trait loci (mQTL), and protein quantitative trait loci (pQTL) data. Summary Data-Based Mendelian Randomization (SMR) and Bayesian colocalization analyses were employed to investigate causal relationships between gene expression and urolithiasis, while external validation and multivariable MR controlled for confounding factors. Seven genes were identified as significantly associated with urolithiasis, with LMAN2, NUCKS1, and L3MBTL3 highlighted as key contributors. LMAN2 was positively associated with urolithiasis risk (SMR b = 0.842, FDR < 0.05), with evidence that increased LMAN2 expression elevates stone formation likelihood, supported by findings from DNA methylation and protein level analyses. Conversely, NUCKS1 and L3MBTL3 exhibited protective effects, with NUCKS1 expression negatively associated with urolithiasis and supported by methylation at the cg12081870 site. Bayesian colocalization analysis showed strong shared genetic bases for NUCKS1 and L3MBTL3 with urolithiasis, with further multivariable MR confirming these associations were independent of BMI, smoking, alcohol consumption, and serum calcium levels. Genetic correlation analysis revealed significant positive genetic correlations between LMAN2 and urolithiasis (rg = 1.12, P = 8.11e-11), while NUCKS1 (rg = - 0.60, P = 3.10e-03) and L3MBTL3 (rg = - 0.38, P = 1.20e-03) showed strong negative correlations. These findings provide critical insights into the genetic basis of urolithiasis, identifying LMAN2, NUCKS1, and L3MBTL3 as potential biomarkers and therapeutic targets, offering a pathway toward personalized treatment strategies.
Indexed as
Identifiers
39680155What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.